Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thank you dew :)
i think one analyst indicated pt $52 here - is that if good data?
still holding shares in your charitable account?
Yes—2Q17 is what the PR says.
hi dew :) when are you expecting P3 data? i thought 2Q 2017?
CLCD has enrolled >50% of 2,968 target in SPARTAN phase-3 trial:
http://finance.yahoo.com/news/colucid-pharmaceuticals-provides-spartan-enrollment-130000943.html
Please see #msg-124979400 for related info.
CLCD had $100.2M cash at 9/30/16: #msg-126424565.
CLCD reports additional data from SAMURAI study:
http://finance.yahoo.com/news/colucid-pharmaceuticals-announces-additional-analyses-145443436.html
money printing machine
Another all-time high today (eom).
CLCD reports update from GLADIATOR safety study: #msg-125245097.
Shorted this Junk again at $31 the stock is brutally overbought and i dont see any potential in their migraine drug which is still years away from the market IF ever . The Market is overflooded with very very cheap generic drugs for migraine so how they will make money ?
Without the almost zero interest and massive printing of worthless dollars by FED Mafia then such scams would not trade at these astronomical levels . The whole stock market is a mega bubble which is close to implode .
CLCD Ladenburg Thalmann making positive comments, PT $57, ph 3 data detail bolsters Lasmiditan. Firm believes M&A is a possibility
Positive secondary endpoints from SAMURAI study: #msg-125220925.
All-time intra-day and closing highs today.
CLCD..more detailed data (Samurai) will be presented this Sunday
CLCD’s largest shareholder, NVO, bought $2M of stock in CLCD’s 9/9/16 public offering:
https://www.sec.gov/Archives/edgar/data/1348649/000120919116141046/xslF345X03/doc4.xml
NVO has close to a 20% stake in CLCD.
CLCD selling unspecified amount of stock on unspecified terms:
http://finance.yahoo.com/news/colucid-pharmaceuticals-announces-proposed-public-200100048.html
Here’s The Latest From CoLucid's Lasmiditan Clinical Study http://marketexclusive.com/heres-latest-colucid-pharmaceuticals-inc-nasdaqclcd-lasmiditan-clinical-study/32120/?icd1
Dew, what's your expectation on mkt cap value, fully realized potential ?
I was wondering why CLCD was moving up a bit premarket this AM in about the first half hour but another C stock was up about 100% soI figured that was it until KABOOM! Once the markets opened we ran HUGE on the news and I was alsleep. I figured I would make a bit from those early pre market shares but nothing compared to what we ended up at. I just got lucky.
CLCD moved up nicely in AH.
+124% on the day—not bad.
CLCD early pre market was so beautiful. I was thinking we would run when I went for it but over 100% is awesome. Congrats to everyone who was awake early as I was. Awesome gainer day.
Shorts having their way now.
What a fantastic SHORT opp here ..Another Phase 3 is required and they running out of cash another point is tha the market is full of very very cheap generics for Migraine
CLCD new corporate slide set:
https://t.co/EvjDJv73Cm
CLCD reports positive phase-3 data from SAMURAI study:
#msg-124979400
Valid point. Assuming the uptrend, and three variables of partially proven drug lasmiditan, also the scheduled presentation the the 17th? What am I missing
Who said the news is going to be positive?
I saw that but it seems odd that his shares would be automatically sold if good news was coming next week. He had 15000 shares as of March and has been dumping in 508 blocks, prior to these smaller sells. Why wouldn't the head of Pharma hold out for positive news?
It's 10b5-1 (i.e. automated) selling—see the Form-4 footnote.
nice pop on no news in CLCD...runup into anticipated data I presume...
CLCD had $41.8M cash at 6/30/16—a decline of $12.3M relative to 3/31/16:
http://finance.yahoo.com/news/colucid-pharmaceuticals-announces-2016-second-120000956.html
Results in August or September, not July. Sorry.
From the June 7th press release:
CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, announced today that the last patient has been randomized in its SAMURAI study, the Company’s first Phase 3 pivotal trial of lasmiditan. Per the SAMURAI protocol, the last patient randomized will have up to eight weeks to complete the study. SAMURAI top-line data are expected to be released when available in the third quarter of 2016, with more detailed results to be presented at a symposium during the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) taking place in Glasgow, Scotland on September 17th, 2016.
I expect stock appreciation to rise in anticipation of good results.
CLCD completes SAMARAI enrollment: #msg-123141798.
CLCD starts SPARTAN phase-3 trial: #msg-122768874.
CLCD adds independent director: #msg-121197220.
Cash at 12/31/15 was $64.5M: #msg-120922653.
CLCD +12% on SPA for SPARTAN phase-3 trial:
http://finance.yahoo.com/news/colucid-pharmaceuticals-announces-special-protocol-130000225.html
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
53
|
Created
|
01/03/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |